Technology
Health
Pharmaceutical

Cumberland Pharmaceuticals

$5.88
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.62 (-9.54%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CPIX and other stocks, options, ETFs, and crypto commission-free!

About

Cumberland Pharmaceuticals Inc. Common Stock, also called Cumberland Pharmaceuticals, is a pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Read More Its product include Acetadote, Caldolor, Kristalose, Hepatoren, Vaprisol, Boxaban, Vasculan, Ethyol, Portaban, and Totect. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Employees
80
Headquarters
Nashville, Tennessee
Founded
1999
Market Cap
100.63M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
10.79K
High Today
$6.41
Low Today
$5.91
Open Price
$6.41
Volume
9.39K
52 Week High
$7.29
52 Week Low
$5.03

Collections

Technology
Health
Pharmaceutical
US
North America

News

Guru FocusMar 12

Cumberland Pharmaceuticals Inc (CPIX) Files 10-K for the Fiscal Year Ended on December 31, 2018

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company.

25
Simply Wall StMar 1

Does Cumberland Pharmaceuticals Inc.’s (NASDAQ:CPIX) CEO Salary Reflect Performance?

A. Kazimi became the CEO of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) in 1999. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we’ll look at a snap shot of the business growth. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. The aim of all this is to consider the appropriateness of CEO pay levels. Check out our latest analysis for Cumberland Pharmaceuticals H...

3
PR NewswireFeb 19

Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2018 Financial Results

To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 3259498. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm . Cumberland Pharmaceuticals Inc. is a speci...

2

Earnings

-$0.16
-$0.07
$0.01
$0.10
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.